Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net loss	$ (69,200)	$ (21,109)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	442	1,335
Loss (gain) on disposal of equipment	(75)	8
Noncash interest expense	35	72
Share-based compensation	2,843	2,966
Writeoff of in process R&D	50,618	0
Change in fair value of derivative liability	0	556
ROU asset amortization	786	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	63	(1,379)
Other long-term assets	0	25
Accounts payable	(193)	194
Accrued expenses	427	(1,848)
Operating lease liability	(747)
Settlement of derivative liability	0	(1,050)
Net cash used in operating activities	(15,001)	(20,230)
Cash flows from investing activities:
Purchases of property and equipment	(791)	(23)
Asset acquisition costs	(318)	0
Proceeds from sale of equipment	115	55
Net cash (used in) provided by investing activities	(994)	32
Cash flows from financing activities:
Proceeds from issuance of common stock	0	60,482
Issuance costs from issuance of common stock	0	(6,319)
Repayment of borrowings under loan	(5,625)	(3,750)
Net cash (used in) provided by financing activities	(5,625)	50,413
Net change in cash, cash equivalents and restricted cash	(21,620)	30,215
Cash, cash equivalents and restricted cash at beginning of period	47,339	25,566
Cash, cash equivalents and restricted cash at end of period	25,719	55,781
Supplemental disclosure of cash flow information
Cash paid for interest	226	686
Supplemental disclosure of financing activities
Deferred offering costs included in accrued expenses	0	(116)
Conversion of preferred units	0	129,870
Payment to non-participating Compass LLC investors, within accrued expenses	0	(69)
ROU asset acquired through operating leases	5,148	0
Acquisition of Trigr Therapeutics, Inc.	$ 50,300	$ 0